-
Merck Is Up 40% In 2018: What's Driving The Rally?
Thursday, November 29, 2018 - 5:11pm | 868Read More...Large-cap pharma stocks have had a decent 2018, with strong earnings momentum primarily responsible for the optimism in the space. Tax cuts enabled companies to augment cash reserves, giving them flexibility to pursue inorganic growth to enrich product pipelines. Here's how large...
-
BMO Downgrades Pfizer After Q3 Print, Says Risk-Reward 'Fairly Balanced'
Thursday, November 1, 2018 - 10:54am | 438Read More...Pfizer Inc. (NYSE: PFE) reported mixed third-quarter results Tuesday that triggered a downgrade by BMO Capital Markets. The Analyst Analyst Alex Arfaei downgraded Pfizer from Outperform to Market Perform and lowered the price target from $47 to $46. The Thesis Pfizer's changed...
-
BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position
Friday, April 27, 2018 - 3:12pm | 378Read More...Bristol-Myers Squibb Co (NYSE: BMY) is down 24 percent from its year-to-date peak, and one Street expert said the price is just right. The Rating BMO Capital Markets analyst Alex Arfaei upgraded Bristol-Myers from Underperform to Market Perform and maintained a $47 price target. The Thesis...
-
BMO's Bearish Stance On Eli Lilly Comes To An End
Friday, April 13, 2018 - 11:00am | 479Read More...The bearish case for Eli Lilly And Co (NYSE: LLY)'s stock is based on multiple concerns, but the stock's decline since the beginning of the year implies a better risk-to-reward profile, according to BMO Capital Markets. The Analyst BMO's Alex Arfaei upgraded Eli Lilly from...
-
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers
Monday, July 24, 2017 - 3:29pm | 444Read More...Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) both release their second quarter earnings reports this week. According to BMO Capital, investors should be buying Merck and selling Bristol-Myers ahead of earnings. Despite Merck being on the verge of...
-
Looking For A Better Entry Point, BMO Downgrades Zoetis Shares
Tuesday, June 13, 2017 - 2:39pm | 251Read More...Citing upcoming risks and not enough upside, BMO Capital Markets analyst Alex Arfaei has downgraded Zoetis Inc (NYSE: ZTS) to Market Perform. “Although we expect a good 2Q17, we doubt it will meaningfully change the company's long-term growth prospects. With consensus estimates rising to...
-
Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers
Saturday, May 6, 2017 - 9:03am | 517Read More...BMO Capital Markets earlier this week downgraded shares of Bristol-Myers Squibb Co (NYSE: BMY), citing strong near-term headwinds and the lower odds of a takeout. Near-Term Headwinds Analyst Alex Arfaei listed a few near-term evens he believes will likely further increase uncertainty about...
-
Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval
Wednesday, May 3, 2017 - 2:41pm | 407Read More...Merck & Co., Inc. (NYSE: MRK) traders that haven't already done so should mark May 10 on their calendars. The company announced in early January the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab)....
-
Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals
Friday, December 16, 2016 - 12:22pm | 343Read More...Investors appear to be pleased with Eli Lilly and Co (NYSE: LLY)'s business after the company updated the investment community with short- and longer-term guidance. Eli Lilly's stock gained more than 5 percent on Thursday and was trading higher by another 1.50 percent at $72.45 ahead of Friday's...
-
Last Night's Election - A Series Of Fortunate Events For Big Pharma
Wednesday, November 9, 2016 - 12:06pm | 440Read More...Pharmaceutical investors could breathe a sigh of relief after Donald Trump won the race to the White House, at least according to Alex Arfaei of BMO Capital Markets. Arfaei commented in a research report on Wednesday that a Trump presidency, coupled with a Republican Congress and the apparent...
-
BMO Capital Upgrades Merck To Outperform, Bullish On Co
Saturday, August 6, 2016 - 11:52am | 328Read More...On Friday, BMO Capital Markets analyst Alex Arfaei upgraded shares of Merck & Co., Inc. (NYSE: MRK) from Market Perform to Outperform, boosting his price target by $10, to $72. Bristol said that its CheckMate-026 study in first-line NSCLC had not managed to meet its primary PFS endpoint, and...
-
Merck's Q2 Good, But Not Good Enough, Says BMO
Monday, August 1, 2016 - 2:12pm | 471Read More...Despite topping the Street view, BMO said the second-quarter results of Merck & Co., Inc. (NYSE: MRK) is not "good enough" to change its Market Perform rating on the stock. Merck's quarterly revenue was about 1 percent above consensus and 1.5 percent above BMO's forecast, while EPS of $0.93 was...
-
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
Monday, July 18, 2016 - 12:02pm | 586Read More...BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...
-
BMO Shows Concern With AbbVie's Major Growth Drivers, Downgrades To Market Perform
Friday, June 10, 2016 - 12:52pm | 326Read More...BMO Capital Markets analyst Alex Arfaei is more concerned about AbbVie Inc. (NASDAQ: ABBV) due to increased uncertainty about big growth drivers. In the absence of it, the analyst downgraded the stock to Market Perform from Outperform and reduced the price target to $66 from $70. The analyst...
-
BMO Valeant Reaction: 10-K Could Give Investors Confidence To Value Shares Above $60
Monday, March 21, 2016 - 3:20pm | 247Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are selling off on Monday afternoon, following a higher morning amid news that the company will move on from its current CEO. The stock is still up 6 percent on the day. While Wall Street's reaction is mixed, one analyst is giving his...
